Lilly
2Q Revenues: $5.8 billion (+8%)
2Q Earnings: $1.0 billion (+35%)
YTD Revenues: $11.1 billion (+8%)
YTD Earnings: $2.2 billion (-24%)
Comments: The increase in worldwide volume was due to 8% pharmaceutical growth driven by Trulicity, with sales up 139% to $480.2 million and other new products, including Taltz ($139 million, +618%), Jardiance ($103.2 million, +157%), and Cyramza ($186.3 million, +27%). These increases were partially offset by decreased volumes for Cialis, flat at $627.3 million, Zyprexa, down 33% to $140.8 million, Alimta, down 12% to $532.9 million, and Strattera, down 17% to $186.6 million. Revenue in the U.S. increased 15% to $3.3 billion, due to higher realized prices for several pharmaceutical products, primarily driven by Cialis and Forteo, and increased volume for new products, driven by Trulicity, Taltz, Basaglar, Jardiance and Lartruvo. Revenue outside the U.S. decreased 1% to $2.5 billion, due to the loss of exclusivity of Zyprexa in Japan and Cymbalta in Canada and Europe, as well as increased competition, lower realized prices and loss of exclusivity for Alimta in several countries.